- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06654752
소아과의 폐악화에 대한 간소화된 치료 (STOP PEDS RCT)
소아과 무작위 대조 시험(STOP PEDS RCT)에서 폐 악화의 간소화된 치료
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
연구 개요
상태
정황
상세 설명
The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.
Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.
The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.
Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:
- Clinic throat swab substudy
- Home throat and nasal swab substudy
- Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Erika Enright
- 전화번호: 206-897-1922
- 이메일: eenright@uw.edu
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- 모병
- The Children's Hospital Alabama & University of Alabama at Birmingham
-
수석 연구원:
- Christopher Fowler, MD
-
연락하다:
- Valerie Tarn
- 전화번호: 2056385134
- 이메일: vtarn@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, 미국, 85713
- 모병
- Tucson Cystic Fibrosis Center
-
수석 연구원:
- Cori Daines, MD
-
연락하다:
- Elizabeth (Lisa) Ryan
- 이메일: elizabethryan@arizona.edu
-
-
California
-
Los Angeles, California, 미국, 90027
- 모병
- Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
-
수석 연구원:
- Martha McKinney, MD
-
연락하다:
- Ariana Teame, BA
- 이메일: ateame@chla.usc.edu
-
Palo Alto, California, 미국, 94304
- 모병
- Stanford University
-
연락하다:
- Tina Conti, BSRC, RRT, RRT-NPS, C-NPT
- 이메일: tconti@stanford.edu
-
수석 연구원:
- Lori WaiHang Lee, MD
-
San Diego, California, 미국, 92123
- 아직 모집하지 않음
- Rady Children's Hospital at University of California San Diego
-
연락하다:
- Lisa Ramos, CRC
- 이메일: lramosvallejo@health.ucsd.edu
-
수석 연구원:
- Kathryn Akong, MD
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital of Colorado
-
수석 연구원:
- Jordana Hoppe, MD
-
연락하다:
- Mary Cross
- 이메일: Mary.Cross@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Children's Healthcare of Atlanta & Emory University
-
연락하다:
- Joy Dangerfield
- 이메일: jdanger@emory.edu
-
수석 연구원:
- Ajay Kasi, MD
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
-
수석 연구원:
- Maria Dowell, MD
-
연락하다:
- Lisa Gallo, CRC
- 전화번호: 312-227-2473
- 이메일: lgallo@luriechildrens.org
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Riley Hospital for Children & Indiana University
-
연락하다:
- Lisa Bendy
- 이메일: lbendy@iu.edu
-
수석 연구원:
- D. B. Sanders, MD, MS
-
연락하다:
- Misty Thompson
- 이메일: misthomp@iu.edu
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 모병
- University of Iowa
-
연락하다:
- Mary Teresi
- 이메일: mary-teresi@uiowa.edu
-
수석 연구원:
- Anthony Fischer, MD
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins Hospital, Johns Hopkins University
-
연락하다:
- Jamelia Maynard
- 이메일: jmaynar8@jhmi.edu
-
수석 연구원:
- Peter Mogayzel, MD, PhD, MBA
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- 모병
- Boston Children's Hospital & Harvard University
-
연락하다:
- Monica Ulles
- 이메일: monica.ulles@childrens.harvard.edu
-
수석 연구원:
- Gregory Sawicki, MD
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109-5212
- 모병
- University of Michigan Health System
-
연락하다:
- Dawn Kruse
- 이메일: dmkruse@med.umich.edu
-
수석 연구원:
- Samya Nasr, MD
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55404
- 모병
- Children's Hospitals and Clinics of Minnesota
-
수석 연구원:
- Brooke Moore, MD
-
연락하다:
- Danniella Balangoy
- 이메일: Danniella.Balangoy@childrensmn.org
-
Minneapolis, Minnesota, 미국, 55455
- 모병
- The Minnesota Cystic Fibrosis Center & University of Minnesota
-
수석 연구원:
- Samuel Goldfarb, MD
-
연락하다:
- Alyssa Perry
- 이메일: ahperry@umn.edu
-
-
Missouri
-
Kansas City, Missouri, 미국, 64108
- 모병
- Children's Mercy Hospital
-
연락하다:
- Jana Lomonte
- 이메일: jblomonte@cmh.edu
-
수석 연구원:
- Hugo Escobar, MD
-
St Louis, Missouri, 미국, 63110
- 모병
- St. Louis Children's Hospital & Washington University School of Medicine
-
수석 연구원:
- Jessica Pittman, MD
-
연락하다:
- Taylor Haas, RN, BSN
- 이메일: koenigt@wustl.edu
-
-
New York
-
Rochester, New York, 미국, 14642
- 모병
- University of Rochester Medical Center Strong Memorial
-
연락하다:
- Barbara Johnson, RN
- 이메일: Barbara_johnson@urmc.rochester.edu
-
수석 연구원:
- Matthew McGraw, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- 모병
- University of North Carolina at Chapel Hill
-
수석 연구원:
- Jennifer Goralski, MD
-
연락하다:
- Caroline Flowers, CRC
- 이메일: caroline_flowers@med.unc.edu
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital Medical Center
-
수석 연구원:
- Gary McPhail, MD
-
연락하다:
- Sharon Donnelly, RN, BSN, CPN
- 이메일: sharon.kadon@cchmc.org
-
-
Oregon
-
Portland, Oregon, 미국, 97239-3098
- 모병
- Oregon Health & Science University
-
연락하다:
- Pierce Nusbaum
- 이메일: nusbaum@ohsu.edu
-
수석 연구원:
- Kelvin MacDonald, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia & University of Pennsylvania
-
수석 연구원:
- Clement Ren, MD, MBA
-
연락하다:
- Matthew Gari
- 이메일: garim@chop.edu
-
연락하다:
- Erin Donnelly
- 이메일: donnellye4@chop.edu
-
Pittsburgh, Pennsylvania, 미국, 15224
- 모병
- Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
-
수석 연구원:
- Daniel Weiner, MD
-
연락하다:
- Tyler Johnston, RN
- 이메일: ateame@chla.usc.edu
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina
-
수석 연구원:
- Sylvia E Szentpeter, MD
-
연락하다:
- Anushka Phadke, CRC
- 전화번호: 843-792-4656
- 이메일: phadke@musc.edu
-
연락하다:
- Sarah Shine, CRC
- 전화번호: 843-792-1221
- 이메일: shinesa@musc.edu
-
-
Texas
-
Dallas, Texas, 미국, 75235
- 모병
- University of Texas Southwestern & Children's Health
-
수석 연구원:
- Preeti Sharma, MD
-
연락하다:
- Lindsay Allen, CRC
- 이메일: Lindsay.Allen@utsouthwestern.edu
-
Houston, Texas, 미국, 77030
- 모병
- Texas Children's Hospital & Baylor College of Medicine
-
수석 연구원:
- Fadel Ruiz, MD
-
연락하다:
- Mayel Yepez
- 이메일: Mayel.YepezDonado@bcm.edu
-
-
Vermont
-
Burlington, Vermont, 미국, 05401
- 모병
- Vermont Children's Hospital & University of Vermont Medical Center
-
수석 연구원:
- Thomas Lahiri, MD
-
연락하다:
- Zachary Dichard
- 이메일: Zachary.Dichard@uvmhealth.org
-
-
Virginia
-
Richmond, Virginia, 미국, 23298
- 모병
- Virginia Commonwealth University
-
연락하다:
- Aleksander Subotic, CRC
- 이메일: aleksandar.subotic@vcuhealth.org
-
수석 연구원:
- Michael T. Schechter, MD
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
수석 연구원:
- Margaret Rosenfeld, MD
-
연락하다:
- Marissa Nelson, CRC
- 전화번호: 206-987-3921
- 이메일: marissa.nelsen@seattlechildrens.org
-
연락하다:
- Elizabeth Gore, RN, MPH
- 전화번호: 206-987-3317
- 이메일: Liz.Gore@seattlechildrens.org
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- 모병
- University of Wisconsin
-
수석 연구원:
- Hara Levy, MD
-
연락하다:
- Nikki Cole, BS, RRT, CCRC
- 이메일: ndondlinger@wisc.edu
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- Children's Wisconsin & Medical College of Wisconsin
-
수석 연구원:
- Nicholas Antos, MD
-
연락하다:
- Laura Robertson, CCRC
- 이메일: lrobertson@mcw.edu
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6H 3V4
- 모병
- British Columbia Children's Hospital
-
수석 연구원:
- Jonathan Rayment, MD
-
연락하다:
- Ronak S Ravandi
- 이메일: ronak.salamatravandi@bcchr.ca
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 0A4
- 모병
- The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
-
수석 연구원:
- Felix Ratjen, MD
-
연락하다:
- Claire Crompton
- 이메일: claire.crompton@sickkids.ca
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Age
- For main cohort and non-HEMT cohort: age 6 to <19 years
- For preschool cohort: age 3 to <6 years
-
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- sweat chloride ≥ 60 mEq/liter
- two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
-
Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study
-
Highly Effective Modulator Therapy
- For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
- For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
-
For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry
-
For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations
-
Ability to receive text messages and access the internet
Exclusion Criteria:
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
- Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
- Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
- History of solid organ transplant
- History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
- Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
- Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
- Treatment with chronic oral antibiotics other than azithromycin at enrollment
- Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Immediate Antibiotics
Increased airway clearance plus early initiation of oral antibiotics |
Increase airway clearance and start 14 days of preselected oral antibiotics right away |
|
실험적: Tailored Therapy
Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve |
Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
One-year change in pulmonary function by spirometry-measured ppFEV1
기간: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease. |
1 year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
One-Year change in pulmonary function by LCI
기간: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity [FRC]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level. |
1 year
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recovery to baseline by ppFEV1 and CRISS following a PEx
기간: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Recovery to baseline by Lung Clearance Index (LCI)
기간: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Safety Endpoint 1: Cumulative oral antibiotic exposure
기간: 1 year
|
Compare cumulative oral antibiotic exposure in each treatment arm. |
1 year
|
|
Safety Endpoint 2: Number of respiratory illnesses
기간: 1 year
|
Compare the number of respiratory illnesses reported over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
기간: 28 days
|
Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm. |
28 days
|
|
Safety Endpoint 4: Number of PEx treated with IV antibiotics
기간: 1 year
|
Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
기간: 28 days
|
Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm. |
28 days
|
|
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
기간: 1 year
|
Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm. |
1 year
|
|
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
기간: 1 year
|
Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm. |
1 year
|
|
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
기간: 1 year
|
Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm. |
1 year
|
|
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
기간: 1 year
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm. |
1 year
|
|
Qualitative Assessment 1: Caregivers' experience managing study treatment
기간: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Qualitative Assessment 2: Study treatment impact on child and family daily life
기간: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Health care costs 1: Total estimated cost of antibiotics
기간: 1 year
|
Compare total estimated cost of antibiotics used over the course of the study between treatment arms. |
1 year
|
|
Health care costs 2: Health care utilization
기간: 1 year
|
Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits. |
1 year
|
|
Health care costs 3: Parent work productivity measures (WPAI)
기간: 1 year
|
To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment. |
1 year
|
|
Preschool and non-HEMT Pilot Cohort Primary Feasibility
기간: 28 days
|
Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx). |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
기간: 28 days
|
Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
기간: 28 days
|
Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
기간: 28 days
|
Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
기간: 28 days
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
기간: 28 days
|
Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
기간: 28 days
|
Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
기간: 28 days
|
Measure the proportion of approached patients that enrolls. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
기간: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
기간: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
기간: 28 days
|
Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm. |
28 days
|
|
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
기간: 1 year
|
Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms. |
1 year
|
|
Clinic Throat Swab Substudy 2: Microbiota Measures
기간: 1 year
|
Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments. |
1 year
|
|
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
기간: 28 days
|
Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis. |
28 days
|
|
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
기간: 28 days
|
Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx). |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
기간: 28 days
|
Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
기간: 28 days
|
Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
기간: 28 days
|
Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment. |
28 days
|
|
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
기간: 28 days
|
Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy. |
28 days
|
|
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
기간: 28 days
|
Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study. |
28 days
|
|
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
기간: 14 days
|
Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study. |
14 days
|
|
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
기간: 28 days
|
Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28). |
28 days
|
|
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
기간: 28 days
|
Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state. |
28 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
기간: 14 days
|
Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
기간: 14 days
|
Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
기간: 14 days
|
Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
기간: 14 days
|
Describe changes in sleep time from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
기간: 14 days
|
Compare changes in resting HR to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
기간: 14 days
|
Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
기간: 14 days
|
Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
기간: 14 days
|
Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
기간: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
기간: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
기간: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
기간: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Margaret Rosenfeld, MD, MPH, Seattle Children's Hospital
- 수석 연구원: D. B. Sanders, MD, MS, Indiana University
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .